VRG Therapeutics

VRG Therapeutics is a private, pre-clinical stage biotech based in Budapest, Hungary, specializing in AI-powered miniprotein drug discovery. The company's core technology platform, comprising ISEP™ and CREATe™, enables the rapid design and optimization of therapeutic peptides with sub-nanomolar affinity and extreme selectivity. While initially targeting neurodegenerative diseases, VRG's versatile platform supports a diverse pipeline and collaborations in cell and gene therapy, positioning it to address high-value, undrugged targets. The company appears to be in a growth phase, securing grants, expanding its team, and initiating an international roadshow.

Proprietary AI-powered miniprotein platform combining ISEP™ (AI-driven de novo scaffold selection) and CREATe™ (wet-lab directed evolution) for rapid design of highly selective, stable therapeutic peptides and protein components.

VRG operates in the highly competitive AI-driven drug discovery sector, competing with global peers like Insilico Medicine, Exscientia, and Recursion. Its specific focus on engineered miniproteins also places it against other peptide-focused biotechs and large pharma internal efforts, requiring it to demonstrate superior speed, selectivity, and a validated pipeline.